Form D · Biotechnology
C4 Therapeutics, Inc.
Cambridge, MA · CIK 0001662579
Offering snapshot reported Jan 11, 2016 · SEC filing
- Reported sold
- $70.3M Offering amount: $73.5M
- Investors reported
- 55 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 29, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 11, 2016 | Initial | $70,315,000 | No comparison | 55 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-254901
Source: Form D, filed Jan 11, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kenneth Anderson | Director |
| Bihua Chen | Director |
| Marc Cohen | Director, Executive |
| Alain Cohen | Director |
| Bruce Downey | Director |
| Jay Eastman | Director |
| Jason Fisherman | Director, Executive |
| Ronald W. Kaiser | Director |
| Elena Prokupets | Director |
| Malcolm S. Salter | Director |
| William M. Scalzulli | Director |
| Miles Stuchin | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
675 West Kendall Street
Cambridge, MA, 02142
Cambridge, MA, 02142